Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 2018

1.

Toxicity and efficacy of defined doses of CD4(+) donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant.

Alyea EP, Soiffer RJ, Canning C, Neuberg D, Schlossman R, Pickett C, Collins H, Wang Y, Anderson KC, Ritz J.

Blood. 1998 May 15;91(10):3671-80.

PMID:
9573003
[PubMed - indexed for MEDLINE]
Free Article
2.

T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation.

Drobyski WR, Hessner MJ, Klein JP, Kabler-Babbitt C, Vesole DH, Margolis DA, Keever-Taylor CA.

Blood. 1999 Jul 15;94(2):434-41. Erratum in: Blood 2000 Feb 15;95(4):1137.

PMID:
10397710
[PubMed - indexed for MEDLINE]
Free Article
3.

CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation.

Giralt S, Hester J, Huh Y, Hirsch-Ginsberg C, Rondón G, Seong D, Lee M, Gajewski J, Van Besien K, Khouri I, Mehra R, Przepiorka D, Körbling M, Talpaz M, Kantarjian H, Fischer H, Deisseroth A, Champlin R.

Blood. 1995 Dec 1;86(11):4337-43.

PMID:
7492795
[PubMed - indexed for MEDLINE]
Free Article
4.

Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.

Posthuma EF, Marijt EW, Barge RM, van Soest RA, Baas IO, Starrenburg CW, van Zelderen-Bhola SL, Fibbe WE, Smit WM, Willemze R, Falkenburg JH.

Biol Blood Marrow Transplant. 2004 Mar;10(3):204-12.

PMID:
14993886
[PubMed - indexed for MEDLINE]
5.

Randomized trial of CD8+ T-cell depletion in the prevention of graft-versus-host disease associated with donor lymphocyte infusion.

Soiffer RJ, Alyea EP, Hochberg E, Wu C, Canning C, Parikh B, Zahrieh D, Webb I, Antin J, Ritz J.

Biol Blood Marrow Transplant. 2002;8(11):625-32.

PMID:
12463482
[PubMed - indexed for MEDLINE]
6.

T-cell--depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect.

Alyea E, Weller E, Schlossman R, Canning C, Webb I, Doss D, Mauch P, Marcus K, Fisher D, Freeman A, Parikh B, Gribben J, Soiffer R, Ritz J, Anderson K.

Blood. 2001 Aug 15;98(4):934-9.

PMID:
11493435
[PubMed - indexed for MEDLINE]
Free Article
8.

Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies.

Spitzer TR, McAfee S, Sackstein R, Colby C, Toh HC, Multani P, Saidman S, Weyouth DW, Preffer F, Poliquin C, Foley A, Cox B, Andrews D, Sachs DH, Sykes M.

Biol Blood Marrow Transplant. 2000;6(3A):309-20.

PMID:
10905768
[PubMed - indexed for MEDLINE]
9.

Conversion to full donor chimerism following donor lymphocyte infusion is associated with disease response in patients with multiple myeloma.

Orsini E, Alyea EP, Chillemi A, Schlossman R, McLaughlin S, Canning C, Soiffer RJ, Anderson KC, Ritz J.

Biol Blood Marrow Transplant. 2000;6(4):375-86.

PMID:
10917573
[PubMed - indexed for MEDLINE]
10.

Comparative outcomes of T-cell-depleted and non-T-cell-depleted allogeneic bone marrow transplantation for chronic myelogenous leukemia: impact of donor lymphocyte infusion.

Sehn LH, Alyea EP, Weller E, Canning C, Lee S, Ritz J, Antin JH, Soiffer RJ.

J Clin Oncol. 1999 Feb;17(2):561-8.

PMID:
10080600
[PubMed - indexed for MEDLINE]
11.

Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation.

Collins RH Jr, Shpilberg O, Drobyski WR, Porter DL, Giralt S, Champlin R, Goodman SA, Wolff SN, Hu W, Verfaillie C, List A, Dalton W, Ognoskie N, Chetrit A, Antin JH, Nemunaitis J.

J Clin Oncol. 1997 Feb;15(2):433-44.

PMID:
9053463
[PubMed - indexed for MEDLINE]
12.

Phase I study of high-stringency CD8 depletion of donor leukocyte infusions after allogeneic hematopoietic stem cell transplantation.

Orti G, Lowdell M, Fielding A, Samuel E, Pang K, Kottaridis P, Morris E, Thomson K, Peggs K, Mackinnon S, Chakraverty R.

Transplantation. 2009 Dec 15;88(11):1312-8. doi: 10.1097/TP.0b013e3181bbf382.

PMID:
19996931
[PubMed - indexed for MEDLINE]
13.

Prevention of graft-versus-host disease in high risk patients by depletion of CD4+ and reduction of CD8+ lymphocytes in the marrow graft.

Herrera C, Torres A, García-Castellano JM, Roman J, Martin C, Serrano J, Falcon M, Alvarez MA, Gomez P, Martinez F.

Bone Marrow Transplant. 1999 Mar;23(5):443-50.

PMID:
10100557
[PubMed - indexed for MEDLINE]
Free Article
14.

Long-term follow-up of T cell-depleted allogeneic bone marrow transplantation in refractory multiple myeloma: importance of allogeneic T cells.

Huff CA, Fuchs EJ, Noga SJ, O'Donnell PV, Ambinder RF, Diehl L, Borrello I, Vogelsang GB, Miller CB, Flinn IA, Brodsky RA, Marcellus D, Jones RJ.

Biol Blood Marrow Transplant. 2003 May;9(5):312-9.

PMID:
12766881
[PubMed - indexed for MEDLINE]
15.

Donor leukocyte infusions for recurrent hematologic malignancies after allogeneic bone marrow transplantation: impact of infused and residual donor T cells.

Verdonck LF, Petersen EJ, Lokhorst HM, Nieuwenhuis HK, Dekker AW, Tilanus MG, de Weger RA.

Bone Marrow Transplant. 1998 Dec;22(11):1057-63.

PMID:
9877267
[PubMed - indexed for MEDLINE]
Free Article
16.

Impact of prophylactic donor leukocyte infusions on mixed chimerism, graft-versus-host disease, and antitumor response in patients with advanced hematologic malignancies treated with nonmyeloablative conditioning and allogeneic bone marrow transplantation.

Dey BR, McAfee S, Colby C, Sackstein R, Saidman S, Tarbell N, Sachs DH, Sykes M, Spitzer TR.

Biol Blood Marrow Transplant. 2003 May;9(5):320-9.

PMID:
12766882
[PubMed - indexed for MEDLINE]
17.

Allogeneic peripheral blood progenitor cells for treatment of relapse after bone marrow transplantation.

Glass B, Majolino I, Dreger P, Scimè R, Santoro A, Vasta S, Suttorp M, Haferlach T, Schmitz N.

Bone Marrow Transplant. 1997 Oct;20(7):533-41.

PMID:
9337054
[PubMed - indexed for MEDLINE]
Free Article
18.

Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.

Slavin S, Naparstek E, Nagler A, Ackerstein A, Kapelushnik J, Or R.

Exp Hematol. 1995 Dec;23(14):1553-62.

PMID:
8542946
[PubMed - indexed for MEDLINE]
19.

Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.

Gürman G, Arat M, Ilhan O, Konuk N, Beksaç M, Celebi H, Ozcan M, Arslan O, Ustün C, Akan H, Uysal A, Koç H.

Cytotherapy. 2001;3(4):253-60.

PMID:
12171713
[PubMed - indexed for MEDLINE]
20.

CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission.

Soiffer RJ, Fairclough D, Robertson M, Alyea E, Anderson K, Freedman A, Bartlett-Pandite L, Fisher D, Schlossman RL, Stone R, Murray C, Freeman A, Marcus K, Mauch P, Nadler L, Ritz J.

Blood. 1997 Apr 15;89(8):3039-47.

PMID:
9108425
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk